Calumet, Inc. (CLMT) director acquires 5,053 shares via RSU settlement
Rhea-AI Filing Summary
Calumet, Inc. reported that one of its directors acquired 5,053 shares of common stock, par value $0.01 per share, on 12/04/2025 through the settlement of restricted stock units at a price of $0 per share.
After this transaction, the director directly beneficially owned 24,733 shares of Calumet common stock. The related derivative position of 5,053 restricted stock units was reduced to zero as they were fully converted into common stock, with each unit economically equivalent to one share and 100% vested.
Positive
- None.
Negative
- None.
FAQ
What insider transaction did Calumet, Inc. (CLMT) report in this filing?
A director of Calumet, Inc. acquired 5,053 shares of common stock, par value $0.01 per share, on 12/04/2025 through the settlement of restricted stock units.
At what price were the Calumet, Inc. (CLMT) shares acquired by the director?
The 5,053 shares of Calumet, Inc. common stock were acquired at a stated price of $0 per share in connection with the restricted stock unit settlement.
How many Calumet, Inc. (CLMT) shares does the director own after this transaction?
Following the reported transaction, the director directly beneficially owned 24,733 shares of Calumet, Inc. common stock.
What happened to the director’s restricted stock units in this Calumet, Inc. filing?
The director’s 5,053 restricted stock units were converted into common stock, reducing the number of restricted stock units beneficially owned to 0.
What is a restricted stock unit in the context of Calumet, Inc. (CLMT)?
Each restricted stock unit is described as the economic equivalent of one share of Calumet, Inc. common stock and becomes payable either in shares or their cash value when vested.
What is the reporting person’s relationship to Calumet, Inc. in this Form 4?
The reporting person is identified as a Director of Calumet, Inc. and the filing is made by one reporting person on an individual basis.